Survival without severe long-term effects in childhood leukemia survivors
Severe Toxicity Free Survival Following Childhood Acute Lymphoblastic Leukemia
This study looks at how many childhood leukemia survivors can live without serious health problems in the years after their treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5000 (estimated) |
| Ages | 0 Years and up |
| Sex | All |
| Sponsor | Rigshospitalet, Denmark Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Copenhagen) |
| Trial ID | NCT05639673 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the long-term health impacts of severe toxicities in survivors of childhood acute lymphoblastic leukemia (ALL). It focuses on quantifying the incidence of 21 defined severe health conditions that may arise after treatment. By utilizing follow-up data from an international collaboration of ALL consortia across Europe, the US, and Australia, the study seeks to determine the likelihood of surviving without these severe toxicities within the first five years post-diagnosis. The findings will help in understanding the cumulative burden of these adverse effects on young survivors.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals who were diagnosed with ALL at age 18 or younger and are now at least five years post-diagnosis.
Not a fit: Patients diagnosed with ALL less than five years ago will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved monitoring and management strategies for long-term health in childhood leukemia survivors.
How similar studies have performed: Previous studies have highlighted the long-term health impacts of childhood cancer treatments, indicating that this approach is building on established findings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosed with ALL ≥5 years ago * \<18 years of age at time of ALL diagnosis Exclusion Criteria: * None
Where this trial is running
Copenhagen
- Kjeld Schmiegelow — Copenhagen, Denmark (Recruiting)
Study contacts
- Principal investigator: Kjeld Schmiegelow, DMSc — Rigshospitalet, Denmark
- Study coordinator: Camilla Grud Nielsen, MD
- Email: camilla.grud.nielsen@regionh.dk
- Phone: +4528450302
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.